TY - JOUR A1 - Risinggård, H. K. A1 - Cooil, S. A1 - Mazzola, F. A1 - Hu, D. A1 - Kjaervik, Marit A1 - Østli, E. R. A1 - Patil, N. A1 - Preobrajenski, A. A1 - Ewans, A. D. A1 - Breiby, D. W. A1 - Trinh, T. T. A1 - Wells, J. W. T1 - Degradation of the chemotherapy drug 5-fluorouracil on medical-grade silver surfaces N2 - The degradation of the chemotherapy drug 5-fluorouracil by a non-pristine metal surfaces is studied.Using density functional theory, X-ray photoelectron spectroscopy and X-ray absorption spectroscopy we show that the drug is entirely degraded by medical-grade silver surfaces, already at body temperature,and that all of the fluorine has left the molecule, presumably as HF. Remarkably, this degradation is even more severe than that reported previously for 5-fluorouracil on a pristine monocrystalline silver surface(in which case 80% of the drug reacted at body temperature) [1]. We conclude that the observed reaction is due to a reaction pathway, driven by H to F attraction between molecules on the surface, which results in the direct formation of HF; a pathway which is favoured when competing pathways involving reactive Ag surface sites are made unavailable by environmental contamination. Our measurements indicate that realistically cleaned, non-pristine silver alloys, which are typically used in medical applications, can result in severe degradation of 5-fluorouracil, with the release of HF – a finding which may have important implications for the handling of chemotherapy drugs. KW - Surface science KW - Chemotherapy KW - DFT KW - Photoemission KW - Fluorouracil KW - Silver PY - 2018 U6 - https://doi.org/10.1016/j.apsusc.2017.11.221 SN - 0169-4332 VL - 435 SP - 1213 EP - 1219 PB - Elsevier CY - Amsterdam, The Netherlands AN - OPUS4-43450 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER - TY - CONF A1 - Abad Andrade, Carlos Enrique A1 - Florek, S. A1 - Becker-Ross, H. A1 - Huang, M.-D. A1 - Recknagel, Sebastian A1 - Jakubowski, Norbert A1 - Panne, Ulrich T1 - Following fluorinated drugs by molecular absorption spectrometry – from cancer cells to body fluids N2 - Fluorine has been widely introduced into pharmaceutical drugs. Due to the high C-F bond strength, a single atom substitution with fluorine produces drastic desirable and tunable changes in the molecular properties. However, the clinical monitoring of these drugs is not straightforward. Organofluorine compounds are elusive for a non-targeted analysis; a significant problem in fluorine determination is the lack of suitable detection techniques. Standard atomic absorption and emission spectrometers cannot access fluorine, because their resonance lines lie in the VUV spectral range below 100 nm. In the case of conventional inductively coupled argon plasmas (ICP), the plasma energy is too low to generate a significant population of excited fluorine atoms. Recently, our group introduces high-resolution continuum source absorption spectrometry (HR-CS MAS) as a new way for the indirect monitoring of fluorinated compounds. Main benefits of HR-CS-MAS includes low limits of detection, complete analyte recovery, simple to no sample preparation, and short time analysis. T2 - 16th Annual Congress of International Drug Discovery Science and Technology 2018 CY - Cambridge, MA, USA DA - 16.08.2018 KW - Fluorine KW - Anti-cancer KW - Capecitabine KW - Fluorouracil KW - HR-CS-MAS PY - 2018 AN - OPUS4-45822 LA - eng AD - Bundesanstalt fuer Materialforschung und -pruefung (BAM), Berlin, Germany ER -